Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis to acquire biopharmaceutical firm Endocyte for $2.1bn
Swiss drugmaker Novartis has agreed to acquire US-based biopharmaceutical firm, Endocyte, in a deal valued at around $2.1bn.
Drug Discovery
-
19 Oct 2018
-
18 Oct 2018
Diurnal puts hold on US development of adrenal drug Chronocort
Diurnal Group has decided to put a hold on all activities relating to the US development of its adrenal drug Chronocort following a failure in a recently concluded phase 3 trial in adults with congenital adrenal hyperplasia (CAH).
-
17 Oct 2018
US firm Revolution Medicines buys Warp Drive Bio
US-based Revolution Medicines has acquired Warp Drive Bio for an undisclosed sum as part of its efforts to expand drug discovery portfolio.
-
16 Oct 2018
HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics
HiFiBiO Therapeutics has acquired H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development of novel immuno-oncology therapeutics.
-
15 Oct 2018
Alliqua BioMedical, Adynxx enter into merger deal
Alliqua BioMedical has entered into a merger agreement with Adynxx to create a clinical-stage pharmaceutical firm, which will focus on development of therapies for pain and inflammation.
-
12 Oct 2018
Carrick licenses global rights to BTG’s ovarian cancer drug
Carrick Therapeutics has acquired global licensing rights to develop and commercialize BTG’s ovarian cancer drug BTG945, which has been renamed as CT900.
-
11 Oct 2018
Mundipharma buys Spanish biosimilars company Cinfa Biotech
Mundipharma, a global network of privately-owned independent associated companies, has acquired Spanish biosimilars development company Cinfa Biotech from Infarco for an undisclosed price.
-
10 Oct 2018
Neurocrine Biosciences, Jnana Therapeutics to discover medicines for CNS disorders
Neurocrine Biosciences and Jnana Therapeutics have entered into a research collaboration to discover novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders.
-
09 Oct 2018
Inovio develops DNA-encoded monoclonal antibody checkpoint inhibitor
Inovio Pharmaceuticals said that it has completed animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4.
-
08 Oct 2018
Sitryx launches with $30m funding to develop disease-modifying therapeutics
New biopharmaceutical company Sitryx has been launched with $30m fundraising for the development of disease modifying therapeutics in immunometabolism.